Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

Andrew Rowland, Mafalda Dias, Michael Wiese, Ganessan Kichenadasse, Ross McKinnon, Christos Karapetis, Michael Sorich

    Research output: Contribution to journalLetter

    5 Citations (Scopus)
    Original languageEnglish
    Number of pages1
    JournalBritish Journal of Cancer
    Issue number11
    Publication statusPublished - 2015

    Cite this